162 related articles for article (PubMed ID: 35256781)
21. Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models.
Kim WG; Zhao L; Kim DW; Willingham MC; Cheng SY
Thyroid; 2014 Feb; 24(2):260-9. PubMed ID: 23731250
[TBL] [Abstract][Full Text] [Related]
22. Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells.
Bolf EL; Gillis NE; Davidson CD; Cozzens LM; Kogut S; Tomczak JA; Frietze S; Carr FE
Mol Carcinog; 2021 Dec; 60(12):874-885. PubMed ID: 34534367
[TBL] [Abstract][Full Text] [Related]
23. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.
Lee WK; Kim WG; Fozzatti L; Park S; Zhao L; Willingham MC; Lonard D; O'Malley BW; Cheng SY
Endocr Relat Cancer; 2020 Apr; 27(4):209-220. PubMed ID: 31977311
[TBL] [Abstract][Full Text] [Related]
24. Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation.
Hwang E; Doolittle WKL; Zhu YJ; Zhu X; Zhao L; Yu Y; Cheng SY
Oncogene; 2023 Oct; 42(41):3075-3086. PubMed ID: 37634007
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
26. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
27. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.
Guigon CJ; Kim DW; Zhu X; Zhao L; Cheng SY
Endocrinology; 2010 Nov; 151(11):5528-36. PubMed ID: 20844001
[TBL] [Abstract][Full Text] [Related]
28. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B
Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851
[TBL] [Abstract][Full Text] [Related]
29. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
30. Novel oncogenic actions of TRbeta mutants in tumorigenesis.
Guigon CJ; Cheng SY
IUBMB Life; 2009 May; 61(5):528-36. PubMed ID: 19391168
[TBL] [Abstract][Full Text] [Related]
31. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
32. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
Li W; Reeb AN; Sewell WA; Elhomsy G; Lin RY
PLoS One; 2013; 8(5):e65095. PubMed ID: 23724124
[TBL] [Abstract][Full Text] [Related]
34. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
35. FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
Cao S; Wang Z; Gao X; He W; Cai Y; Chen H; Xu R
J Exp Clin Cancer Res; 2018 Sep; 37(1):220. PubMed ID: 30189871
[TBL] [Abstract][Full Text] [Related]
36. Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression.
Kim WG; Zhu X; Kim DW; Zhang L; Kebebew E; Cheng SY
Endocrinology; 2013 Jan; 154(1):25-35. PubMed ID: 23183175
[TBL] [Abstract][Full Text] [Related]
37. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
38. SRY‑related HMG box‑2 role in anaplastic thyroid cancer aggressiveness is related to the fibronectin 1 and PI3K/AKT pathway.
Wang P; Shang J; Zhao J; Wang K; Guo L; Gu J; Wang W
Mol Med Rep; 2020 Mar; 21(3):1201-1207. PubMed ID: 31922212
[TBL] [Abstract][Full Text] [Related]
39. Autonomous functions of murine thyroid hormone receptor TRα and TRβ in cochlear hair cells.
Dettling J; Franz C; Zimmermann U; Lee SC; Bress A; Brandt N; Feil R; Pfister M; Engel J; Flamant F; Rüttiger L; Knipper M
Mol Cell Endocrinol; 2014 Jan; 382(1):26-37. PubMed ID: 24012852
[TBL] [Abstract][Full Text] [Related]
40. Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Gu G; Gelsomino L; Covington KR; Beyer AR; Wang J; Rechoum Y; Huffman K; Carstens R; Andò S; Fuqua SA
Breast Cancer Res Treat; 2015 Apr; 150(3):535-45. PubMed ID: 25820519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
